BioVie Management
Management criteria checks 1/4
BioVie's CEO is Cuong Viet Do, appointed in Apr 2021, has a tenure of 4.92 years. total yearly compensation is $860.15K, comprised of 71.8% salary and 28.2% bonuses, including company stock and options. directly owns 0.14% of the company’s shares, worth $15.09K. The average tenure of the management team and the board of directors is 4.8 years and 0.8 years respectively.
Key information
Cuong Viet Do
Chief executive officer
US$860.1k
Total compensation
| CEO salary percentage | 71.85% |
| CEO tenure | 4.9yrs |
| CEO ownership | 0.1% |
| Management average tenure | 4.8yrs |
| Board average tenure | less than a year |
Recent management updates
Recent updates
Here's Why We're Watching BioVie's (NASDAQ:BIVI) Cash Burn Situation
Feb 13
BioVie: Recent Data In Alzheimer's Suggests +100% Upside Potential Within A Year
Oct 14BioVie: Possibly Setting Up For Success With Alzheimer's And Parkinson's Results Imminent
Sep 06BioVie: Four Potential Catalysts Around The Corner
Jun 07CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2025 | n/a | n/a | -US$17m |
| Sep 30 2025 | n/a | n/a | -US$19m |
| Jun 30 2025 | US$860k | US$618k | -US$18m |
| Mar 31 2025 | n/a | n/a | -US$19m |
| Dec 31 2024 | n/a | n/a | -US$26m |
| Sep 30 2024 | n/a | n/a | -US$27m |
| Jun 30 2024 | US$777k | US$618k | -US$33m |
| Mar 31 2024 | n/a | n/a | -US$37m |
| Dec 31 2023 | n/a | n/a | -US$43m |
| Sep 30 2023 | n/a | n/a | -US$51m |
| Jun 30 2023 | US$2m | US$618k | -US$50m |
| Mar 31 2023 | n/a | n/a | -US$49m |
| Dec 31 2022 | n/a | n/a | -US$41m |
| Sep 30 2022 | n/a | n/a | -US$31m |
| Jun 30 2022 | US$5m | US$300k | -US$26m |
| Mar 31 2022 | n/a | n/a | -US$150m |
| Dec 31 2021 | n/a | n/a | -US$145m |
| Sep 30 2021 | n/a | n/a | -US$143m |
| Jun 30 2021 | US$2m | n/a | -US$184m |
Compensation vs Market: Cuong Viet's total compensation ($USD860.15K) is above average for companies of similar size in the US market ($USD578.00K).
Compensation vs Earnings: Cuong Viet's compensation has increased whilst the company is unprofitable.
CEO
Cuong Viet Do (59 yo)
Mr. Cuong Viet Do, M.B.A. is Chief Executive Officer, President and Director of Option Therapeutics Inc. He is Independent Director of Adagene (Suzhou) Limited. Mr. Do is Independent Director of Adagene In...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.9yrs | US$860.15k | 0.14% $ 15.1k | |
| CFO, Treasurer & Corporate Secretary | 7.4yrs | US$420.62k | 0.011% $ 1.2k | |
| Executive VP of R&D and Chief Medical Officer | 4.3yrs | US$666.05k | 0.014% $ 1.5k | |
| Senior Vice President of Operations | 2.3yrs | no data | no data | |
| Senior Vice President of Liver Disease Program | no data | no data | no data | |
| Senior Vice President of Manufacturing & Development | 7.2yrs | no data | no data | |
| Senior Vice President of Alzheimer's Disease Program | 4.7yrs | no data | no data | |
| Senior VP & Chief Regulatory Officer | no data | no data | no data |
Experienced Management: BIVI's management team is considered experienced (4.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 9.8yrs | US$860.15k | 0.14% $ 15.1k | |
| Independent Director | 5.8yrs | US$150.15k | 0.040% $ 4.2k | |
| Independent Chairman | 9.3yrs | US$170.95k | 0.0092% $ 972.9 | |
| Member of Corporate Advisory Board | less than a year | no data | no data | |
| Independent Director | 8.7yrs | US$159.31k | 0.0028% $ 293.5 | |
| Member of Corporate Advisory Board | less than a year | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Member of Corporate Advisory Board | less than a year | no data | no data | |
| Chair of Corporate Advisory Board | less than a year | no data | no data | |
| Member of Corporate Advisory Board | less than a year | no data | no data | |
| Member of Corporate Advisory Board | less than a year | no data | no data | |
| Member of Corporate Advisory Board | less than a year | no data | no data |
Experienced Board: BIVI's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/12 22:48 |
| End of Day Share Price | 2026/03/12 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioVie Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Tyler Bussian | Brookline Capital Markets |
| Jay Olson | Oppenheimer & Co. Inc. |